Cambridge-based biotech firm, Axcella Health Inc., has been making waves in the clinical stage biotechnology sector in the U.S. The company's unique approach to treating complex diseases and enhancing health has put it on the radar of investors and industry professionals alike. Axcella Health's lead product candidates AXA1665 and AXA1125 are both in various stages of clinical trials. AXA1665 is currently in Phase 2 clinical trials focused on reducing the risk of overt hepatic encephalopathy recurrence, while AXA1125 is in Phase 2b for treating non-alcoholic steatohepatitis and Phase 2a for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc., but rebranded as Axcella Health Inc. in June 2016. With its innovative solutions to complex health issues, Axcella Health is poised for growth and success in the biotech industry.
Axcella Health's ticker is AXLA
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Axcella Health
It is axcellatx.com
Axcella Health is in the Healthcare sector
Axcella Health is in the Biotechnology industry
The following five companies are Axcella Health's industry peers: